Medicine access programs (MAPs) provide Australian cancer patients with opportunities to access treatment options not available on the PBS. They represent a small but important proportion of available treatments. What are some of the challenges pharmacists and institutions face in supporting MAPs? A snapshot of how these are managed by different Australian hospitals may give inspiration for your site. In theme with this year’s ASM, this session will also touch on potential inequities. These include the limited ability for public hospital patients to access cost-share programs, lack of information on MAP availability and challenges in access to small, remote or regional sites. There is also the growing disparity between public and private hospitals in accessing PBS listed high-cost inpatient therapies. Are MAPs the answer to bridge this gap? What is the role of the pharmacist in this evolving landscape? Join me for a discussion on all things MAPs.